OncoNano Medicine Announces First Patient Dosed in Phase 1 Study Evaluating ONM-501 in Patients with Advanced Solid Tumors and Lymphomas
The ONM-501 trial ( NCT06022029 ) is a multicenter Phase 1, dose escalation and dose expansion study in patients with advanced solid tumors and lymphomas.
- The ONM-501 trial ( NCT06022029 ) is a multicenter Phase 1, dose escalation and dose expansion study in patients with advanced solid tumors and lymphomas.
- ONM-501 features dual STING activation, with the polymers used to construct the micelles binding to and activating STING alongside the payload critical to activation.
- During the combinatorial dose escalation and expansion cohort segments of the trial, ONM-501 will be dosed in combination with Regeneron’s Libtayo® (cemiplimab-rwlc), an anti-PD-1 monoclonal antibody.
- OncoNano and Regeneron have entered into a clinical trial supply agreement for this ONM-501 study.